Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsFRA:PR80 +6.68%38 PB Ratio is 11.34 as of Jul. 14, 2026, which is 138% above its 10-year median of 4.77. GuruFocus rates FRA:PR80 with a GF Score™ of 38/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,228 Biotechnology companies, BLS Pharmaceuticals ranks worse than 87.3% on this metric.
The historical rank and industry rank for BLS Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:PR80'
s PB Ratio Range Over the Past 10 Years
Min: 0.63 Med: 4.77 Max: 25.56
Current: 10.66
During the past 13 years, BLS Pharmaceuticals's highest PB Ratio was 25.56. The lowest was 0.63. And the median was 4.77.
FRA:PR80's PB Ratio is ranked worse than 87.3% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs FRA:PR80: 10.66
During the past 12 months, BLS Pharmaceuticals's average Book Value Per Share Growth Rate was 160.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -4.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BLS Pharmaceuticals was 137.50% per year. The lowest was -71.60% per year. And the median was -21.00% per year.
Back to Basics: PB Ratio
BLS Pharmaceuticals (FRA:PR80) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BLS Pharmaceuticals PB Ratio Related Terms
BLS Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BLS Pharmaceuticals (FRA:PR80) has a PB Ratio of 11.34 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BLS Pharmaceuticals and its competitors. This is 138% above median its historical median of 4.77. Over the past decade, BLS Pharmaceuticals' PB Ratio has ranged from 0.63 to 25.56. According to the industry distribution chart, BLS Pharmaceuticals ranks #1072 out of 1228 companies in the Biotechnology industry, placing it in the top 87.3%.
Is BLS Pharmaceuticals' PB Ratio too high?
BLS Pharmaceuticals' current PB Ratio of 11.34 is 138% above median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 25.56. The Biotechnology industry median PB Ratio is 2.89. BLS Pharmaceuticals' value of 11.34 is 293.1% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #1072 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' PB Ratio compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #1072 out of 1228 companies for PB Ratio. This places BLS Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.89. BLS Pharmaceuticals' value of 11.34 is 293.1% above this benchmark. Historically, BLS Pharmaceuticals' own PB Ratio has ranged from 0.63 to 25.56 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 2.89, BLS Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current PB Ratio of 11.34 is 293.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current PB Ratio is 11.34, which is 138% above median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current PB Ratio is 11.34, which is 138% above median its 10-year median of 4.77 and 293.1% above the Biotechnology industry median of 2.89. BLS Pharmaceuticals' overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current PB Ratio is 11.34 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
PB Ratio: 11.34 (138% above median its 10-year median of 4.77)
GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
Industry Position: 293.1% above the Biotechnology median (#1072 of 1228)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
38GF Score
Get the complete analysis for FRA:PR80
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
